Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology

Tuesday, April 15, 2008 General News
Email Print This Page Comment
Font : A-A+

REHOVOT, Israel and JERSEY CITY, New Jersey, April 14 Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leader inthe development of microRNA-based diagnostic and therapeutic products,announced today it has signed an agreement with University of California,Irvine School of Medicine (UC Irvine), relating to the development andvalidation of diagnostic tests based on the company's microRNA technology.The tests are designed to differentiate squamous versus non-squamous lungcancer, differentiate mesothelioma from adenocarcinoma, and identify cancersof unknown primary (CUP) origin.

"This agreement is key to the successful implementation of our businessstrategy for our diagnostic products," noted Amir Avniel, President and CEOof Rosetta Genomics. "With its experienced research team and state-of-the-artCLIA-certified laboratory, UC Irvine is an excellent collaborator for testsdeveloped applying our microRNA technology."

"We believe this agreement is an important step towards bringingmicroRNA-based diagnostics to patients and physicians," said Dr. JohnKrolewski, from UC Irvine. "There is a large body of research into thesignificant potential microRNAs hold as powerful biomarkers, and we areexcited to develop and validate assays using Rosetta Genomics' microRNAtechnology."

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.

About University of California, Irvine School of Medicine

The University of California, Irvine is a top-ranked university dedicatedto research, scholarship and community service. Founded in 1965, UCI is amongthe fastest-growing University of California campuses, with more than 27,000undergraduate and graduate students and about 1,800 faculty members. TheSchool of Medicine is among the top 50 in the nation for research fundingexpenditures and is home to one Nobel Prize winner, four members of theInstitute of Medicine and five National Academy of Sciences members. Currentfaculty oversee the education and training of more than 400 medical students,600 residents and 120 graduate students.

http://www.healthaffairs.uci.edu/

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs .Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The company expects that the first microRNA diagnostic tests applying itstechnology will be launched by licensed clinical laboratories in the UnitedStates in 2008.

http://www.rosettagenomics.com

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the role of microRNAs in human physiology and disease, thepotential of microRNAs in the diagnosis and treatment of disease and theexpected timing of submission for approval and launch of diagnostic testsusing our microRNA technology constitute


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook